APA (7th ed.) Citation

T, G., J, P., JG, F., N, G., L, P., E, G., . . . E, L. (2024). Rethinking surgical revisions: Impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib. British journal of cancer, 130(7), 1141. https://doi.org/10.1038/s41416-024-02580-3

Chicago Style (17th ed.) Citation

T, Gaillard, et al. "Rethinking Surgical Revisions: Impact of the MonarchE Trial on Axillary Dissection in Hormone-positive HER2-negative Early Breast Cancer Patients Potentially Eligible for Abemaciclib." British Journal of Cancer 130, no. 7 (2024): 1141. https://doi.org/10.1038/s41416-024-02580-3.

MLA (9th ed.) Citation

T, Gaillard, et al. "Rethinking Surgical Revisions: Impact of the MonarchE Trial on Axillary Dissection in Hormone-positive HER2-negative Early Breast Cancer Patients Potentially Eligible for Abemaciclib." British Journal of Cancer, vol. 130, no. 7, 2024, p. 1141, https://doi.org/10.1038/s41416-024-02580-3.